Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study.
paper
Cited
Public
Unavailable
- Authors
- Zhou, Hang; Rentsch, Christopher T; Cheng, Zhongshan; Kember, Rachel L; Nunez, Yaira Z; Sherva, Richard M; Tate, Janet P; Dao, Cecilia; Xu, Ke; Polimanti, Renato; Farrer, Lindsay A; Justice, Amy C; Kranzler, Henry R; Gelernter, Joel; Veterans Affairs Million Veteran Program
- Year
- 2020
- Journal
- JAMA psychiatry
- PMID
- 32492095
- DOI
- 10.1001/jamapsychiatry.2020.1206
- PMCID
- PMC7270886
IMPORTANCE: With the current opioid crisis, it is important to improve understanding of the biological mechanisms of opioid use disorder (OUD). OBJECTIVES: To detect genetic risk variants for OUD and determine genetic correlations and causal association with OUD and other traits. DESIGN, SETTING, AND PARTICIPANTS: A genome-wide association study of electronic health record-defined OUD in the Million Veteran Program sample was conducted, comprising 8529 affected European American individuals and 71β―200 opioid-exposed European American controls (defined by electronic health record trajectory analysis) and 4032 affected African American individuals and 26β―029 opioid-exposed African American controls. Participants were enrolled from January 10, 2011, to May 21, 2018, with electronic health record data for OUD diagnosis from October 1, 1999, to February 7, 2018. Million Veteran Program results and additional OUD case-control genome-wide association study results from the Yale-Penn and Study of Addiction: Genetics and Environment samples were meta-analyzed (total numbers: European American individuals, 10β―544 OUD cases and 72β―163 opioid-exposed controls; African American individuals, 5212 cases and 26β―876 controls). Data on Yale-Penn participants were collected from February 14, 1999, to April 1, 2017, and data on Study of Addiction: Genetics and Environment participants were collected from 1990 to 2007. The key result was replicated in 2 independent cohorts: proxy-phenotype buprenorphine treatment in the UK Biobank and newly genotyped Yale-Penn participants. Genetic correlations between OUD and other traits were tested, and mendelian randomization analysis was conducted to identify potential causal associations. MAIN OUTCOMES AND MEASURES: Main outcomes were International Classification of Diseases, Ninth Revision-diagnosed OUD or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision-diagnosed OUD (Million Veteran Program), and DSM-IV-defined opioid dependence (Yale-Penn and Study of Addiction: Genetics and Environment). RESULTS: A total of 114β―759 individuals (101β―016 men [88%]; mean [SD] age, 60.1 [12.8] years) were included. In 82β―707 European American individuals, a functional coding variant (rs1799971, encoding Asn40Asp) in OPRM1 (ΞΌ-opioid receptor gene, the main biological target for opioid drugs; OMIM 600018) reached genome-wide significance (G allele: Ξ²β=β-0.066 [SEβ=β0.012]; Pβ=β1.51βΓβ10-8). The finding was replicated in 2 independent samples. Single-nucleotide polymorphism-based heritability of OUD was 11.3% (SEβ=β1.8%). Opioid use disorder was genetically correlated with 83 traits, including multiple substance use traits, psychiatric illnesses, cognitive performance, and others. Mendelian randomization analysis revealed the following associations with OUD: risk of tobacco smoking, depression, neuroticism, worry neuroticism subcluster, and cognitive performance. No genome-wide significant association was detected for African American individuals or in transpopulation meta-analysis. CONCLUSIONS AND RELEVANCE: This genome-wide meta-analysis identified a significant association of OUD with an OPRM1 variant, which was replicated in 2 independent samples. Post-genome-wide association study analysis revealed associated pleiotropic characteristics. Recruitment of additional individuals with OUD for future studies-especially those of non-European ancestry-is a crucial next step in identifying additional significant risk loci.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Exploring the genetic overlap between substance use disorder and educational attainment. | Cabana-DomΓnguez J et al. | β | 2026 | β |
| Large-scale behavioral characterization of oxycodone self-administration in heterogeneous stock rats reveals initial analgesic effects are associated with addiction-like behaviors. | Kallupi M et al. | β | 2026 | β |
| Mapping the genetic landscape across 14 psychiatric disorders. | Grotzinger AD et al. | β | 2026 | β |
| Transcription factors implicated in substance use disorder, from immediate early genes to altered gene expression. | Orr E et al. | β | 2026 | β |
| Addiction Susceptibility: Genetic Factors, Personality Traits, and Epigenetic Interactions with the Gut Microbiome. | Borrego-Ruiz A et al. | β | 2025 | β |
| Chronic overlapping pain conditions in individuals with active opioid use disorder: a descriptive study of syringe program participants. | Rausch J et al. | β | 2025 | β |
| Elucidating neuroepigenetic mechanisms to inform targeted therapeutics for brain disorders. | Weekley BH et al. | β | 2025 | β |
| Exploration of Genetic Liability to Insomnia and Substance Use Disorders in Patients With Bipolar Disorder. | Melhuish Beaupre LM et al. | β | 2025 | β |
| Genetic and Epigenetic Approaches to Opioid Use Disorder. | Ranadeva ND et al. | β | 2025 | β |
| Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder. | Annis AC et al. | β | 2025 | β |
| Genome-wide association study reveals multiple loci for nociception and opioid consumption behaviors associated with heroin vulnerability in outbred rats. | Kuhn BN et al. | β | 2025 | β |
| Genomic structural equation study reveals links between anorexia nervosa and delay discounting and lack of perseverance but not other facets of impulsivity. | Bianchi SB et al. | β | 2025 | β |
| Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases. | Stratford JK et al. | β | 2025 | β |
| Impulsivity facets and substance use involvement: insights from genomic structural equation modeling. | Vilar-RibΓ³ L et al. | β | 2025 | β |
| Influence of multi-species data on gene-disease associations in substance use disorder using random walk with restart models. | Castaneda EU et al. | β | 2025 | β |
| Multiomic Network Analysis Identifies Dysregulated Neurobiological Pathways in Opioid Addiction. | Sullivan KA et al. | β | 2025 | β |
| Opioid-Related Pharmacogenomic Variants in a Retrospective Cohort of High-Risk Hospitalized Infants. | Barq RM et al. | β | 2025 | β |
| Precision medicine in substance use disorders: Integrating behavioral, environmental, and biological insights. | Guerrin CGJ et al. | β | 2025 | β |
| Scoping review of associations between cytochrome P450 3A4/5 single nucleotide polymorphisms and risk factors for fentanyl overdose. | Petrovitch D et al. | β | 2025 | β |
| Utility of Candidate Genes From an Algorithm Designed to Predict Genetic Risk for Opioid Use Disorder. | Davis CN et al. | β | 2025 | β |
| Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants. | Wang L et al. | β | 2025 | β |
| An emerging multi-omic understanding of the genetics of opioid addiction. | Johnson EO et al. | β | 2024 | β |
| Complex NADASE Infusions Improve Clinical Outcome in Substance Use Disorder: Descriptive Annotation in Fifty Cases. | Blum K et al. | β | 2024 | β |
| Differential etiologic associations of heroin use and prescription opioid misuse with psychopathology. | Dash GF et al. | β | 2024 | β |
| Epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. | Hoang AT et al. | β | 2024 | β |
| Generalized genetic liability to substance use disorders. | Miller AP et al. | β | 2024 | β |
| Genetic and non-genetic predictors of risk for opioid dependence. | Na PJ et al. | β | 2024 | β |
| Genetic and shared environmental factors explain the association between adolescent polysubstance use and high school noncompletion. | Davis CN et al. | β | 2024 | β |
| Genetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study. | Panday SK et al. | β | 2024 | β |
| Genome-wide analyses reveal shared genetic architecture and novel risk loci between opioid use disorder and general cognitive ability. | Holen B et al. | β | 2024 | β |
| Genome-wide association study of the common retinal disorder epiretinal membrane: Significant risk loci in each of three American populations. | Gelernter J et al. | β | 2024 | β |
| Genomic factors associated with substance use disorder relapse: A critical review. | Al-Marzooqi N et al. | β | 2024 | β |
| Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes. | Toikumo S et al. | β | 2024 | β |
| Opioid trail: Tracking contributions to opioid use disorder from host genetics to the gut microbiome. | Duffy EP et al. | β | 2024 | β |
| Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. | Kazi I et al. | β | 2024 | β |
| Sex and genetic background influence intravenous oxycodone self-administration in the hybrid rat diversity panel. | Duffy EP et al. | β | 2024 | β |
| The genetic landscape of substance use disorders. | Gerring ZF et al. | β | 2024 | β |
| The impact of assortative mating, participation bias and socioeconomic status on the polygenic risk of behavioural and psychiatric traits. | Cabrera-Mendoza B et al. | β | 2024 | β |
| Allele frequency and genotype distribution of the opioid receptor ΞΌ-1 (OPRM1) A118G polymorphism in the Western Saudi population. | Bagher AM et al. | β | 2023 | β |
| A multivariate approach to understanding the genetic overlap between externalizing phenotypes and substance use disorders. | Poore HE et al. | β | 2023 | β |
| A review of the genomics of neonatal abstinence syndrome. | Yen E et al. | β | 2023 | β |
| Cross-phenotype relationship between opioid use disorder and suicide attempts: new evidence from polygenic association and Mendelian randomization analyses. | Huang Y et al. | β | 2023 | β |
| Differences in genetic correlations between posttraumatic stress disorder and alcohol-related problems phenotypes compared to alcohol consumption-related phenotypes. | Bountress KE et al. | β | 2023 | β |
| Evaluating 17 methods incorporating biological function with GWAS summary statistics to accelerate discovery demonstrates a tradeoff between high sensitivity and high positive predictive value. | Moore A et al. | β | 2023 | β |
| Genome- and transcriptome-wide splicing associations with alcohol use disorder. | Huggett SB et al. | β | 2023 | β |
| Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression. | Holen B et al. | β | 2023 | β |
| Identifying genetic loci and phenomic associations of substance use traits: A multi-trait analysis of GWAS (MTAG) study. | Xu H et al. | β | 2023 | β |
| Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. | Johnson EC et al. | β | 2023 | β |
| Methylation and expression quantitative trait loci rs1799971 in the OPRM1 gene and rs4654327 in the OPRD1 gene are associated with opioid use disorder. | Yu J et al. | β | 2023 | β |
| Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. | Zhou H et al. | β | 2023 | β |
| Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. | Hatoum AS et al. | β | 2023 | β |
| New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. | Andreassen OA et al. | β | 2023 | β |
| Phenome-wide Association Analysis of Substance Use Disorders in a Deeply Phenotyped Sample. | Kember RL et al. | β | 2023 | β |
| Specificity in genetic and environmental risk for prescription opioid misuse and heroin use. | Dash GF et al. | β | 2023 | β |
| The evolution of Big Data in neuroscience and neurology. | Dipietro L et al. | β | 2023 | β |
| The Genetically Informed Neurobiology of Addiction (GINA) model. | Bogdan R et al. | β | 2023 | β |
| The Stage-Based Model of Addiction-Using <i>Drosophila</i> to Investigate Alcohol and Psychostimulant Responses. | Cummins-Beebee PN et al. | β | 2023 | β |
| Accelerating Opioid Use Disorders Research by Integrating Multiple Data Modalities. | Bianchi SB et al. | β | 2022 | β |
| Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. | Yuferov V et al. | β | 2022 | β |
| Are prescription misuse and illicit drug use etiologically distinct? A genetically-informed analysis of opioids and stimulants. | Dash GF et al. | β | 2022 | β |
| Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. | Xie X et al. | β | 2022 | β |
| A Systematic Review of Genetic Polymorphisms Associated with Bipolar Disorder Comorbid to Substance Abuse. | de Marco A et al. | β | 2022 | β |
| Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. | Laffont CM et al. | β | 2022 | β |
| CharacterisationΒ of the genetic relationship between the domains of sleep and circadian-related behavioursΒ with substance use phenotypes. | Hatoum AS et al. | β | 2022 | β |
| Clinical, environmental, and genetic risk factors for substance use disorders: characterizing combined effects across multiple cohorts. | Barr PB et al. | β | 2022 | β |
| Common and distinguishing genetic factors for substance use behavior and disorder: an integrated analysis of genomic and transcriptomic studies from both human and animal studies. | Chang XW et al. | β | 2022 | β |
| Convergence of case-specific epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. | Corradin O et al. | β | 2022 | β |
| CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder. | Nagamatsu ST et al. | β | 2022 | β |
| Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. | Kember RL et al. | β | 2022 | β |
| Evaluation of methods incorporating biological function and GWAS summary statistics to accelerate discovery | Moore A et al. | β | 2022 | β |
| Genetic implications in quality palliative care and preventing opioid crisis in cancer-related pain management. | Sumitani M et al. | β | 2022 | β |
| Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. | Hartwell EE et al. | β | 2022 | β |
| Genetic overlap between mood instability and alcohol-related phenotypes suggests shared biological underpinnings. | Icick R et al. | β | 2022 | β |
| Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. | Deak JD et al. | β | 2022 | β |
| Identifying High-Risk Comorbidities Associated with Opioid Use Patterns Using Electronic Health Record Prescription Data. | Jennings MV et al. | β | 2022 | β |
| Molecular genetics of cocaine use disorders in humans. | FernΓ ndez-Castillo N et al. | β | 2022 | β |
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | Gaddis N et al. | β | 2022 | β |
| Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases. | Blum K et al. | β | 2022 | β |
| Nicotine and opioid co-dependence: Findings from bench research to clinical trials. | Custodio L et al. | β | 2022 | β |
| Opioid Use Disorder and Alternative mRNA Splicing in Reward Circuitry. | Huggett SB et al. | β | 2022 | β |
| Parsing genetically influenced risk pathways: genetic loci impact problematic alcohol use via externalizing and specific risk. | Barr PB et al. | β | 2022 | β |
| Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative. | Kusic D et al. | β | 2022 | β |
| Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic. | Smith DM et al. | β | 2022 | β |
| Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans. | Rabinowitz JA et al. | β | 2022 | β |
| Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"? | Blum K et al. | β | 2022 | β |
| Strong and weak cross-inheritance of substance use disorders in a nationally representative sample. | Zhang H et al. | β | 2022 | β |
| Substance use and common contributors to morbidity: A genetics perspective. | Sanchez-Roige S et al. | β | 2022 | β |
| The addiction risk factor: A unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. | Hatoum AS et al. | β | 2022 | β |
| Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. | Love T et al. | β | 2022 | β |
| Using Mendelian randomization to explore the gateway hypothesis: possible causal effects of smoking initiation and alcohol consumption on substance use outcomes. | Reed ZE et al. | β | 2022 | β |
| Why haven't we solved the addiction crisis? | Blum K et al. | β | 2022 | β |
| Analysis of genetic and clinical factors associated with buprenorphine response. | Crist RC et al. | β | 2021 | β |
| Ancestry may confound genetic machine learning: Candidate-gene prediction of opioid use disorder as an example. | Hatoum AS et al. | β | 2021 | β |
| Biomarkers to predict staging and treatment response in opioid dependence: A narrative review. | Vorspan F et al. | β | 2021 | β |
| Cooperative Studies Program (CSP) #572: A Study of Serious Mental Illness in Veterans as a Pathway to personalized medicine in Schizophrenia and Bipolar Illness. | Harvey PD et al. | β | 2021 | β |
| Epigenome-wide study of brain DNA methylation following acute opioid intoxication. | Shu C et al. | β | 2021 | β |
| Exploring the genetic overlap of suicide-related behaviors and substance use disorders. | Colbert SMC et al. | β | 2021 | β |
| Genetics and prescription opioid use (GaPO): study design for consenting a cohort from an existing biobank to identify clinical and genetic factors influencing prescription opioid use and abuse. | Troiani V et al. | β | 2021 | β |
| Genetics of substance use disorders: a review. | Deak JD et al. | β | 2021 | β |
| Genetics of substance use disorders in the era of big data. | Gelernter J et al. | β | 2021 | β |
| Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. | Sherva R et al. | β | 2021 | β |
| Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. | Sanchez-Roige S et al. | β | 2021 | β |
| Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies. | Cozzoli D et al. | β | 2021 | β |
| Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. | Chawar C et al. | β | 2021 | β |
| Integration of evidence across human and model organism studies: A meeting report. | Palmer RHC et al. | β | 2021 | β |
| Molecular genetics of substance use disorders: An umbrella review. | Lopez-Leon S et al. | β | 2021 | β |
| Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality. | Polimanti R et al. | β | 2021 | β |
| Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction. | Karlsson LinnΓ©r R et al. | β | 2021 | β |
| Perspective on Beyond Statistical Significance: Finding Meaningful Effects. | Edenberg HJ | β | 2021 | β |
| Pharmacogenomics of oxycodone: a narrative literature review. | Umukoro NN et al. | β | 2021 | β |
| Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. | Rosoff DB et al. | β | 2021 | β |
| The Cocaine and Oxycodone Biobanks, Two Repositories from Genetically Diverse and Behaviorally Characterized Rats for the Study of Addiction. | Carrette LLG et al. | β | 2021 | β |
| The Gut Microbiome and Substance Use Disorder. | Russell JT et al. | β | 2021 | β |
| The patterns of family genetic risk scores for eleven major psychiatric and substance use disorders in a Swedish national sample. | Kendler KS et al. | β | 2021 | β |
| The phenomics and genetics of addictive and affective comorbidity in opioid use disorder. | Freda PJ et al. | β | 2021 | β |
| Anxiety sensitivity and pain intensity independently predict opioid misuse and dependence in chronic pain patients. | Smit T et al. | β | 2020 | β |
| Evolution of regulatory signatures in primate cortical neurons at cell-type resolution. | Kozlenkov A et al. | β | 2020 | β |